Main Article Content
DLL4-mediated NOTCH1 signaling represents an essential pathway for vascular development and has emerged as an attractive target for angiogenesis-based cancer therapies. However, newly reported toxicity findings raise safety concerns of chronic pathway blockade. Lessons learned from the development of γ-secretase inhibitors (GSIs) might offer insights into how to safely harness this important signaling pathway.
How to Cite
YAN, Minhong. Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vascular Cell, [S.l.], v. 3, n. 1, p. 17, aug. 2011. ISSN 2045-824X. Available at: <https://vascularcell.com/index.php/vc/article/view/10.1186-2045-824X-3-17>. Date accessed: 23 oct. 2021. doi: http://dx.doi.org/10.1186/2045-824X-3-17.